Improving regulation of microbiota transplants

Science

Volumn 358, Issue 6369, 2017, Pages 1390-1391

  Hoffmann, Diane ^a   Palumbo, Francis ^a   Ravel, Jacques ^a   Roghmann, Mary Claire ^a,b   Rowthorn, Virginia ^a   Von Rosenvinge, Erik ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESSIBILITY; BACTERIUM; BIOSAFETY; BIOTECHNOLOGY; EFFICIENCY MEASUREMENT; MICROORGANISM; RESEARCH;

BACTERIUM CULTURE; BIOBANK; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; FECAL MICROBIOTA TRANSPLANTATION; FECES; FECES ANALYSIS; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; INTESTINE FLORA; MEDICAL HISTORY; MEDICAL RESEARCH; MICROBIAL CONSORTIUM; MICROBIAL POPULATION DYNAMICS; NONHUMAN; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SAFETY; SCANNING ELECTRON MICROSCOPY; STOOL BANK; CLOSTRIDIUM INFECTION; MICROBIOLOGY; POLICY; STANDARDS;

BIOLOGICAL SPECIMEN BANKS; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; FECES; GASTROINTESTINAL MICROBIOME; HUMANS; POLICY; SAFETY;

EID: 85040107079     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaq0034     Document Type: Review

References (22)

1. E. van Nood et al., N. Engl. J. Med. 368, 407 (2013).
2. G. Cammarota et al., Aliment. Pharmacol. Ther. 41, 835 (2015).
3. C. R. Kelly et al., Ann. Intern. Med. 165, 609 (2016).
4. www.law.umaryland.edu/programs/health/events/microbiota/
5. F. C. Lessa et al., N. Engl. J. Med. 372, 825 (2015)
6. F. Barbut et al., Clostridium difficile infection in Europe: A CDI Europe report 2013; www.multivu.com/assets/60637/documents/60637-CDI-HCP-Report-original.pdf.
7. Y. Song et al., PLOS ONE 8, e81330 (2013).
8. American College of Obstetricians and Gynecologists, Practice advisory: Vaginal seeding; www.acog.org/About-ACOG/News-Room/Practice-Advisories/Practice-Advisory-Vaginal-Seeding.
9. E. O. Petrof, A. Khoruts, Gastroenterology 146, 1573 (2014).
10. U.S. Food and Drug Administration, Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. Draft guidance for industry. March 2016. www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM488223.pdf?source=govdelivery&utm-medium=email&utm-source=govdelivery.
11. Rebiotix, Comment on FDA-2013-D-0811. 20 June 2016. www.regulations.gov/document?D=FDA-2013-D-0811-0116.
12. Comments on FDA-2013-D-0811. www.regulations.gov/doc ketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dc t=PS&D=FDA-2013-D-0811.
13. U.S. Food and Drug Administration, Tissue Reference Group: FY 2012 Update, 2012; www.fda.gov/biologicsbloodvaccines/tissuetissueproducts/regulationoftissues/ucm152857.htm.
14. A. Khoruts,Comment on FDA-2013-D-0811. 25 April 2016. www.regulations.gov/document?D=FDA-2013-D-0811-0065.
15. M. B. Smith, C. Kelly, E. J. Alm, Nature 506, 290 (2014).
16. R. E. Sachs, C. A. Edelstein, J. Law Biosci. 2, 396 (2015).
17. Written comments from working group member Catherine Duff, Founder and President of the Fecal Transplant Foundation, submitted December 2016; www.law. umaryland.edu/programs/health/events/microbiota/documents/wg3/CatherineDuffComments.pdf.
18. R. E. Sachs, C. A. Edelstein, J. Law Biosci. 2, 396 (2015).
19. M. F. Riley, B. Olle, J. Law Biosci. 2, 742 (2015).
20. A. B. Laakmann, Cardozo Law Rev. 36, 913 (2015).
21. 21 CFR 1271, subparts A-F.
22. American Gastroenterological Association. FMT National Registry; www.gastro.org/patient-care/registries-studies/fmt-registry.